Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia : a one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA)

Taher, A.T.; Porter, J.B.; Viprakasit, V.; Kattamis, A.; Chuncharunee, S.; Sutcharitchan, P.; Siritanaratkul, N.; Galanello, R.; Karakas, Z.; Lawniczek, T.; Habr, D.; Ros, J.; Zhu, Z.; Cappellini, M.D.

Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia : a one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA) / A.T. Taher, J.B. Porter, V. Viprakasit, A. Kattamis, S. Chuncharunee, P. Sutcharitchan, N. Siritanaratkul, R. Galanello, Z. Karakas, T. Lawniczek, D. Habr, J. Ros, Z. Zhu, M.D. Cappellini. - In: BLOOD. - ISSN 0006-4971. - 120:21(2012 Nov), pp. 3258-3258. ((Intervento presentato al 54. convegno ASH Annual Meeting American Society Hematology tenutosi a Atlanta nel 2012.